First cohort of the Sovereign AI Fund supporting UK-based AI companies building in priority sectors.

Funding for UK businesses developing AI solutions that demonstrably improve economic productivity.

Innovate UK is offering up to £25.4 million to support the clinical validation and evaluation of early cancer diagnostic technologies and devices. This funding is for researchers and startups developing innovative solutions for accelerated cancer diagnosis. The key requirement is to demonstrate the clinical validity and evaluability of the proposed technologies.

This UKRI funding opportunity supports academically led experimental medicine studies in humans to understand the causal mechanisms of gambling disorder. It aims to deepen the understanding of how gambling activities, products, and interventions affect individuals with gambling disorder. The funding is open to researchers and academics in the UK, with no specific funding amount mentioned but typical UKRI grants can range significantly.

This UKRI funding opportunity, from the MRC, invites applications to investigate the biological mechanisms behind differing responses to biomedical prevention interventions. The goal is to generate mechanistic evidence in humans to inform precision prevention strategies. Funding is available for projects focused on understanding these response variations.

This funding opportunity is for UK-based research organisations looking to collaborate with the UK Human Functional Genomics Initiative. It aims to advance research in human functional genomics by enabling collaborations with the initiative's resources and expertise. The specific funding amount is not detailed, but the focus is on collaborative research projects within this domain.

The UKRI Translation: MRC Impact Acceleration Awards fund research organisations to de-risk a single, high-risk development step for new medicines, medical devices, diagnostics, or other medical products. This award is for research organisations eligible for MRC funding, with grant amounts typically ranging from £50,000 to £200,000. The key requirement is to generate crucial data that significantly reduces the risk associated with a medical innovation.

The UKRI MRC proof of concept: stage two funding opportunity is for researchers employed at eligible research organizations to develop and test novel therapeutics, medical devices, diagnostics, and other interventions. This grant aims to advance early-stage research towards clinical application. Funding amounts are not explicitly stated but are expected to support significant development milestones.

This UKRI funding opportunity, previously known as the 'Developmental pathway funding scheme: stage one,' supports the development and testing of novel therapeutics, medical devices, diagnostics, and other interventions. It is open to researchers employed at eligible research organizations. The funding aims to advance early-stage medical innovations towards practical application.

This UKRI funding opportunity aims to establish a UK Obesity Research Institute focused on world-leading research into the biomedical drivers of obesity. It seeks to develop targeted interventions for prevention and treatment. The funding is for UK-based research organisations eligible for MRC funding, though specific amounts and application deadlines are not yet detailed.